Fesoterodine Fumarate API

Name	Fesoterodine fumarate
Chinese name	富马酸非索罗定
Cas Number	286930-03-8
Source	India
Qualifications	USDMF/-/-/-/-

The original research company of fesoterodine fumarate sustained-release tablets was Pfizer. It was approved by EMA on April 20, 2007, and was approved by FDA on October 31, 2008. It is a treatment for overactive bladder syndrome. The prodrug, which enters the body, is converted into the active metabolite 5-HMT of a muscarinic receptor antagonist, which can be used for the treatment of frequent urination, urgency, urinary incontinence or a combination of all these symptoms in patients with overactive bladder (OAB) . Fesoterodine is a new generation of tolterodine upgraded drug, with more stable PK characteristics. Two head-to-head studies have shown that fesoterodine 8mg is better than tolterodine 4mg in reducing the onset of UUI; at the same time, fesoterodine can reduce the adverse effects of urinary retention compared with tolterodine. Probability. In 2017, the global urinary incontinence drug treatment market was about US$3.4 billion, with a huge market capacity.

Hot Tags: fesoterodine fumarate api, China, suppliers, manufacturers, factory, customized, price, pricelist, in stock, Escitalopram Oxalate API, Bosentan API, Idebenone API, Edoxaban API, Temozolomide API, Salmeterol Xinafoate API

• Previous: Creboro API
• Next: Fosapidem Dimethyl Meglumine API